表紙
市場調查報告書

嗜鉻細胞瘤:開發中產品分析

Pheochromocytoma - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 200475
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
嗜鉻細胞瘤:開發中產品分析 Pheochromocytoma - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 112 Pages
簡介

嗜鉻細胞瘤是罕見的疾病,一般是非癌性(良性)腫瘤,在腎上腺的細胞內相當發達。症狀有高血壓,強烈頭痛,身體顫抖,呼吸急促,便秘等。危險因子有第二型多發性內分泌腫瘤症、逢希伯-林道症候群(VHL)、第一型神經性纖維瘤等。

本報告提供嗜鉻細胞瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

嗜鉻細胞瘤 - 概要

嗜鉻細胞瘤 - 治療藥的開發

  • 開發平台(管線)概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

嗜鉻細胞瘤 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

嗜鉻細胞瘤的治療藥開發企業

  • Advanced Accelerator Applications SA
  • Exelixis Inc
  • MediaPharma srl
  • OctreoPharm Sciences GmbH
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Valeant Pharmaceuticals International Inc

藥物簡介

嗜鉻細胞瘤 - 暫停中的計劃

嗜鉻細胞瘤 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12161IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H1 2020, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 2 and 2 respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Pheochromocytoma - Overview
  • Pheochromocytoma - Therapeutics Development
  • Pheochromocytoma - Therapeutics Assessment
  • Pheochromocytoma - Companies Involved in Therapeutics Development
  • Pheochromocytoma - Drug Profiles
  • Pheochromocytoma - Dormant Projects
  • Pheochromocytoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pheochromocytoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, H1 2020
  • Pheochromocytoma - Pipeline by Enterome Bioscience SA, H1 2020
  • Pheochromocytoma - Pipeline by Exelixis Inc, H1 2020
  • Pheochromocytoma - Pipeline by Fujifilm Holdings Corp, H1 2020
  • Pheochromocytoma - Pipeline by Gibson Oncology LLC, H1 2020
  • Pheochromocytoma - Pipeline by Ipsen SA, H1 2020
  • Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, H1 2020
  • Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
  • Pheochromocytoma - Pipeline by Oncoceutics Inc, H1 2020
  • Pheochromocytoma - Pipeline by Pfizer Inc, H1 2020
  • Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, H1 2020
  • Pheochromocytoma - Pipeline by Vyriad Inc, H1 2020
  • Pheochromocytoma - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Pheochromocytoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020